Expanding the Armamentarium for Castrate-resistant Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2016.05.022
Abstract: Castrate-resistant prostate cancer (CRPC) is an incurable clinical condition that accounts for the vast majority of the >300 000 recorded deaths from this disease each year across the globe. This high level of mortality is… read more here.
Keywords: prostate cancer; disease; castrate resistant; cancer ... See more keywords
Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development.
Sign Up to like & getrecommendations! Published in 2017 at "ACS chemical biology"
DOI: 10.1021/acschembio.6b01035
Abstract: There is a tremendous need for novel strategies aimed at directly assessing activities of histone modifiers to probe epigenetic determinants associated with disease progression. Here, we developed a high-throughput peptide microarray assay to identify altered… read more here.
Keywords: activity; castrate resistant; prostate cancer; histone ... See more keywords
Effect of Dietary Omega-3 Fatty Acids on Castrate Resistant Prostate Cancer and Tumor Associated Macrophages
Sign Up to like & getrecommendations! Published in 2019 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-019-0168-8
Abstract: Background M2-like macrophages are associated with the pathogenesis of castrate-resistant prostate cancer (CRPC). We sought to determine if dietary omega-3 fatty acids (ω-3 FAs) delay the development and progression of CRPC and inhibit tumor-associated M2-like… read more here.
Keywords: prostate cancer; omega fatty; dietary omega; castrate resistant ... See more keywords
Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/srep40957
Abstract: Androgen receptor variants (AR-Vs) provide a mechanism of therapy evasion in castrate-resistant prostate cancer (CRPC), yet mechanisms of regulation remain largely unknown. Here we investigate the role of Aurora A kinase on AR-Vs in models… read more here.
Keywords: crpc; resistant prostate; castrate resistant; prostate cancer ... See more keywords
Cardiovascular, bone, and metabolic health in men with castrate-resistant prostate cancer treated with androgen deprivation: a matched cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2141077
Abstract: Abstract Background Descriptive data on late effects associated with castrate-resistant prostate cancer (CRPC) are sparse. We aimed to define the timing and incidence of cardiovascular disease (CVD), fractures, and diabetes in a patient population with… read more here.
Keywords: incidence; castrate resistant; prostate cancer; resistant prostate ... See more keywords
Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000001807
Abstract: Two patients with castrate-resistant prostate cancer and symptomatic skeletal metastases underwent F-fluorocholine PET/CT prior to treatment with Ra-dichloride to reveal additional active lesions in the prostate gland and lymph nodes. Subsequent scans performed at the… read more here.
Keywords: soft tissue; fluorocholine pet; prostate cancer; tissue ... See more keywords
Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Supportive and Palliative Care"
DOI: 10.1097/spc.0000000000000620
Abstract: Purpose of review Systemic chemotherapy and second-generation androgen receptor-axis targeted therapies have been in the forefront of management for metastatic castrate-resistant prostate cancer (mCRPC) patients with low or high symptom burden. However, in the recent… read more here.
Keywords: castrate resistant; metastatic castrate; prostate; resistant prostate ... See more keywords
Abstract 5389: A personalized medicine approach to identifying dysregulated epigenetic enzyme activity in the development of castrate-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-5389
Abstract: Purpose: Recent advances in proteomic and chromatin immunoprecipitation tools have been vital in studying cancer epigenetics, but the ability to measure directly the enzyme activities of dysregulated histone-modifiers understudied. We utilize a novel approach to… read more here.
Keywords: medicine; resistant prostate; castrate resistant; approach ... See more keywords
Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.5045
Abstract: 5045Background: Trophoblastic cell-surface antigen (Trop-2) is a transmembrane glycoprotein that is highly expressed in many solid tumors. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate of an anti-Trop-2 humanized antibody with SN-38. Early clinical trials have… read more here.
Keywords: trop expression; prostate cancer; expression; castrate resistant ... See more keywords
Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e16517
Abstract: e16517Background: The concurrent development of cabazitaxel, AA, ENZA, and radium-223 has recently increased the number of therapeutic options for mCRPC. Cabazitaxel is currently approved for mCRPC... read more here.
Keywords: cabazitaxel; metastatic castrate; prostate cancer; castrate resistant ... See more keywords
Progression free survival in patients with castrate resistant metastatic prostate cancer: Does sequence matter?
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.356
Abstract: 356Background: Approval of multiple therapeutic agents for castrate resistant prostate cancer (CPRPC) has improved survival and also quality of life. However, how to optimize sequencing is still an ongoing challenge for most clinicians. Methods: A… read more here.
Keywords: prostate cancer; free survival; castrate resistant; progression free ... See more keywords